TSS
BRNS

Two Sigma Securities’s Barinthus Biotherapeutics BRNS Stock Holding History

Two Sigma Securities’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-16,919
Closed -$39.8K – 2682
2022
Q4 		$39.8K Buy
+16,919
New +$43.1K ﹤0.01% 2194

Other funds holding BRNS

MGIM
M&G Investment Management London, United Kingdom $28.2B AUM 25.87% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $64B AUM 22.64% 1-Year Est. Return
JHU
Johns Hopkins University Baltimore, Maryland $1.38B AUM 9.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Securities's BRNS Position: Q1 2023 in Review

Two Sigma Securities sold out of Barinthus Biotherapeutics (BRNS) in Q1 2023, closing a stake of 16,919 shares — an estimated $39.8K sold.

Two Sigma Securities first reported a position in BRNS in Q4 2022 and held it in 1 quarter. The position peaked at $39.8K in Q4 2022. 13 funds tracked by Wall St. Rank hold BRNS as of Q1 2023.

  • Two Sigma Securities reported no remaining Barinthus Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Two Sigma Securities sold 16,919 Barinthus Biotherapeutics shares in Q1 2023, an estimated $39.8K.
  • Two Sigma Securities first reported a position in Barinthus Biotherapeutics in Q4 2022 and held it in 1 quarter.
  • Two Sigma Securities's Barinthus Biotherapeutics position peaked at $39.8K in Q4 2022.
  • 13 funds tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q1 2023.

Based on Two Sigma Securities's 13F filing for Q1 2023, filed 15 May 2023.